NcXHF

PUNGLIA, HUGHES, AND MUSS
6. Hughes KS, Schnaper LA, Berry D, et al. Lumpectomy plus tamoxifen
with or without irradiation in women 70 years of age or older with early
breast cancer. N Engl J Med. 2004;351:971-977.
7. Allan SG, Rodger A, Smyth JF, et al. Tamoxifen as primary treatment of
breast cancer in elderly or frail patients: a practical management. BMJ
(Clin Res Ed). 1985;290:358.
8. Ellis MJ, Suman VJ, Hoog J, et al. Randomized phase II neoadjuvant comparison
between letrozole, anastrozole, and exemestane for postmenopausal
women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical
and biomarker outcomes and predictive value of the baseline PAM50-
based intrinsic subtype-ACOSOG Z1031. J Clin Oncol. 2011;29:2342-2349.
9. Hughes KS, Schnaper LA, Bellon JR, et al. Lumpectomy plus tamoxifen
with or without irradiation in women age 70 years or older with early
breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013;
31:2382-2387.
10. Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary
dissection in women with invasive breast cancer and sentinel node
metastasis: a randomized clinical trial. JAMA. 2011;305:569-575.
11. Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after
sentinel lymph node dissection with or without axillary dissection in
patients with sentinel lymph node metastases: the American College of
Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 252:426-
432; discussion 2010;432-433.
12. Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery
of the axilla after a positive sentinel node in breast cancer (EORTC
10981-22023 AMAROS): a randomised, multicentre, open-label, phase
3 non-inferiority trial. Lancet Oncol. 2014;15:1303-1310.
13. Nijenhuis MV, Rutgers EJ. Who should not undergo breast conservation?
Breast 22 Suppl. 2013;2:S110-S114.
14. Bartelink H, Maingon P, Poortmans P, et al. Whole-breast irradiation
with or without a boost for patients treated with breast-conserving surgery
for early breast cancer: 20-year follow-up of a randomised phase 3
trial. Lancet Oncol. 2015;16:47-56.
15. Early Breast Cancer Trialists’ Collaborative G, Darby S, McGale P, et al.
Effect of radiotherapy after breast-conserving surgery on 10-year recurrence
and 15-year breast cancer death: meta-analysis of individual patient
data for 10,801 women in 17 randomised trials. Lancet. 2011;378:1707-
1716.
16. Fisher B, Bryant J, Dignam JJ, et al. Tamoxifen, radiation therapy, or
both for prevention of ipsilateral breast tumor recurrence after lumpectomy
in women with invasive breast cancers of one centimeter or less.
J Clin Oncol. 2002;20:4141-4149.
17. Hershman DL, Kushi LH, Shao T, et al. Early discontinuation and nonadherence
to adjuvant hormonal therapy in a cohort of 8,769 early-stage
breast cancer patients. J Clin Oncol. 2010;28:4120-4128.
18. Rayan G, Dawson LA, Bezjak A, et al. Prospective comparison of breast
pain in patients participating in a randomized trial of breast-conserving
surgery and tamoxifen with or without radiotherapy. Int J Radiat Oncol
Biol Phys. 2003;55:154-161.
19. Berrington de Gonzalez A, Curtis RE, Kry SF, et al. Proportion of second
cancers attributable to radiotherapy treatment in adults: a cohort study
in the US SEER cancer registries. Lancet Oncol. 2011;12:353-360.
20. Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in
women after radiotherapy for breast cancer. N Engl J Med. 2013;368:
987-998.
21. Giordano SH, Kuo YF, Freeman JL, et al. Risk of cardiac death after adjuvant
radiotherapy for breast cancer. J Natl Cancer Inst. 2005;97:419-424.
22. Bartelink H, Horiot JC, Poortmans PM, et al. Impact of a higher radiation
dose on local control and survival in breast-conserving therapy of
early breast cancer: 10-year results of the randomized boost versus no
boost EORTC 22881-10882 trial. J Clin Oncol. 2007;25:3259-3265.
23. Whelan TJ, Pignol JP, Levine MN, et al. Long-term results of hypofractionated
radiation therapy for breast cancer. N Engl J Med. 2010;362:513-520.
24. Haviland JS, Owen JR, Dewar JA, et al. The UK Standardisation of
Breast Radiotherapy (START) trials of radiotherapy hypofractionation
for treatment of early breast cancer: 10-year follow-up results of two
randomised controlled trials. Lancet Oncol. 2013;14:1086-1094.
25. Arvold ND, Taghian AG, Niemierko A, et al. Age, breast cancer subtype
approximation, and local recurrence after breast-conserving therapy.
J Clin Oncol. 2011;29:3885-3891.
26. Shi W, Fyles A, Pintilie M, et al. Abstract 1032: Post-menopausal women
with luminal A subtype might not require breast radiotherapy: Preliminary
results from a randomized clinical trial of tamoxifen radiation.
Cancer Res. 2012;72:1032.
27. Jenkins EO, Deal AM, Anders CK, et al. Age-specifıc changes in intrinsic
breast cancer subtypes: a focus on older women. Oncologist. 2014;19:
1076-1083.
28. Albert JM, Pan IW, Shih YC, et al. Effectiveness of radiation for prevention
of mastectomy in older breast cancer patients treated with conservative
surgery. Cancer. 2012;118:4642-4651.
29. Muss HB. Adjuvant chemotherapy in older women with breast cancer:
who and what? J Clin Oncol. 2014;32:1996-2000.
30. Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes
in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin
Oncol. 2010;28:509-518.
31. Muss HB, Tu D, Ingle JN, et al. The benefıts of letrozole in postmenopausal
women with early stage breast cancer who have had fıve years of
tamoxifen are independent of age. Breast Cancer Res and Treatment.
2006;S23.
32. Owusu C, Buist DS, Field TS, et al. Predictors of tamoxifen discontinuation
among older women with estrogen receptor-positive breast cancer.
J Clin Oncol. 2008;26:549-555.
33. Paik S, Tang G, Shak S, et al. Gene expression and benefıt of chemotherapy
in women with node-negative, estrogen receptor-positive breast
cancer. J Clin Oncol. 2006;24:3726-3734.
34. Dowsett M, Sestak I, Lopez-Knowles E, et al. Comparison of PAM50
risk of recurrence score with Oncotype DX and IHC4 for predicting risk
of distant recurrence after endocrine therapy. J Clin Oncol. 2013;31:
2783-2790.
35. Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of
women with early breast cancer: highlights of the St Gallen International
Expert Consensus on the Primary Therapy of Early Breast Cancer
2013. Ann Oncol. 2013;24:2206-2223.
36. Dowsett M, Cuzick J, Wale C, et al. Prediction of risk of distant recurrence
using the 21-gene recurrence score in node-negative and nodepositive
postmenopausal patients with breast cancer treated with
anastrozole or tamoxifen: a TransATAC study. J Clin Oncol. 2010;28:
1829-1834.
37. Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of
the 21-gene recurrence score assay in postmenopausal women with
node-positive, oestrogen-receptor-positive breast cancer on chemotherapy:
a retrospective analysis of a randomised trial. Lancet Oncol.
2010;11:55-65.
38. Early Breast Cancer Trialists’ Collaborative Group, Peto R, Davies C, et
al. Comparisons between different polychemotherapy regimens for
early breast cancer: Meta-analyses of long-term outcome among 100
000 women in 123 randomised trials. Lancet. 2012;379:432-444.
39. de Glas NA, van de Water W, Engelhardt EG, et al. Validity of Adjuvant!
Online program in older patients with breast cancer: a population-based
study. Lancet Oncol. 2014;15:722-729.
40. Muss HB, Berry DA, Cirrincione CT, et al. Adjuvant chemotherapy in
older women with early-stage breast cancer. N Engl J Med. 2009;360:
2055-2065.
54 2015 ASCO EDUCATIONAL BOOK | asco.org/edbook